Early Detection and Screening of Pancreatic Cancer
Abstract
No abstract available.
Image: Columbia University's New Transparent Medical Center. New York, NY, USA.
Downloads
References
Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. Dec 2009;6(12):699-708. [PMID 19806144]
Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis 2010; 28:645-56. [PMID 21088417]
Strimpakos AS, Syrigos KN, Saif MW. The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver 2010; 4:433-49. [PMID 21253292]
Larghi A, Verna EC, Lecca PG, Costamagna G. Screening for pancreatic cancer in high-risk individuals: a call for endoscopic ultrasound. Clin Cancer Res 2009; 15:1907-14. [PMID 19276278]
Nagasaka T, Goel A, TaniguchiN, Mori Y, Sigeyasu K, Yamada E, et al. Power of fecal DNA methylation analysis: Does it lead to development of a noninvasive screening tool for pancreatic cancer? J Clin Oncol 2011; 29(Suppl. 4):Abstract 187. ]
Ahlquist DA. Molecular stool screening for colorectal cancer. Using DNA markers may be beneficial, but large scale evaluation is needed. BMJ 2000; 321:254-5. [PMID 10915110]
Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351:2704-14. [PMID 15616205]
Ahlquist DA. Next-generation stool DNA testing: expanding the scope. Gastroenterology 2009; 136:2068-73. [PMID 19379748]
Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005; 97:1124-32. [PMID 16077070]
Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC 3rd, Sontag S, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 2007; 5:111-7. [PMID 17161655]
Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol 2008; 103:2862-70. [PMID 18759824]
Itzkowitz SH. Incremental advances in excremental cancer detection tests. J Natl Cancer Inst 2009; 101:1225-7. [PMID 19700654]
Nagasaka T, Tanaka N, Cullings HM, Sun DS, Sasamoto H, Uchida T, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst 2009; 101:1244-58. [PMID 19700653]
Owusu-Sarfo K, Asiago V, Gowda N, Shanaiah N, Xi B, Chiorean EG, Raftery D. 1H NMR-based metabolic profiling of serum for the detection of pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 193. ]
Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009; 15:431-40. [PMID 19147747]
Bathe OF, Shaykhutdinov R, Kopciuk K, Weljie AM, McKay A, Sutherland FR, et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev 2011;20:140-7. [PMID 21098649]
Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256:102-5. [PMID 1566048]
Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ Jr, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346:311-20. [PMID 11821507]
Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009; 69:4691-9. [PMID 19435926]
Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 2009; 101:916-27. [PMID 19535783]
Copyright (c) 2011 Tamas A Gonda, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.